Date published: 2026-5-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

CGR19 Inhibitors

CGR19 inhibitors are a class of compounds that specifically target and inhibit the activity of the CGR19 protein, which is likely involved in cellular regulation and signaling, although its precise biological functions may not be fully characterized. CGR19 is suspected to play a role in molecular pathways that influence processes such as cell communication, protein interactions, or the regulation of cellular homeostasis. Inhibition of CGR19 disrupts its normal activities, providing researchers with a means to study the protein's contributions to these pathways. By preventing CGR19 from interacting with other proteins or participating in cellular signaling events, CGR19 inhibitors offer insights into the protein's role in maintaining the balance of specific intracellular processes.

The mechanism of action for CGR19 inhibitors involves binding to key regions of the protein, such as active sites or areas involved in protein-protein interactions, effectively blocking its functional role. By inhibiting CGR19, these compounds allow for the exploration of how cellular pathways are regulated by this protein and what effects its inhibition has on cellular dynamics. Researchers use CGR19 inhibitors to examine how this protein might affect gene expression, protein stability, or cell signaling networks. Additionally, these inhibitors can shed light on how CGR19 contributes to the broader molecular landscape, including its involvement in regulatory networks that control cellular functions such as growth, differentiation, or structural integrity. Through such studies, scientists can develop a clearer picture of how CGR19 operates within the cell and the impact of its inhibition on overall cellular physiology.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

This histone deacetylase inhibitor may alter chromatin structure, potentially leading to the suppression of CGR19 transcription.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

As a DNA methyltransferase inhibitor, it could affect DNA methylation patterns, potentially resulting in the downregulation of CGR19.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$176.00
$426.00
43
(3)

It intercalates DNA and may disrupt transcriptional processes, which could decrease CGR19 expression.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor that may downregulate signaling pathways involved in cell growth, potentially affecting CGR19 expression.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$37.00
$69.00
$109.00
$218.00
$239.00
$879.00
$1968.00
47
(1)

This natural compound may modulate transcription factors or signaling pathways leading to decreased CGR19 expression.

Disulfiram

97-77-8sc-205654
sc-205654A
50 g
100 g
$53.00
$89.00
7
(1)

By chelating metal ions, it could interfere with the metal ion binding activity of CGR19, potentially inhibiting its function and expression.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$138.00
$380.00
101
(4)

It forms DNA adducts which might impair transcription, possibly affecting CGR19 expression.

D,L-Sulforaphane

4478-93-7sc-207495A
sc-207495B
sc-207495C
sc-207495
sc-207495E
sc-207495D
5 mg
10 mg
25 mg
1 g
10 g
250 mg
$153.00
$292.00
$489.00
$1325.00
$8465.00
$933.00
22
(1)

May affect epigenetic regulation and subsequently downregulate CGR19 expression through histone modification.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Another histone deacetylase inhibitor that could reduce the expression of CGR19 by altering chromatin accessibility.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

This PI3K inhibitor might downregulate the PI3K/Akt signaling pathway, potentially impacting CGR19 expression.